Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2012
  • Online publication date: May 2012

9 - Adaptive Design Across Stages of Therapeutic Development

from Section 3


1. GalloP, Chuang-SteinC, DragalinV, et al. Adaptive designs in clinical drug development – An executive summary of the PhRMA working group. J Biopharm Stat 2006; 16: 275–83.
2. KramsM, BurmanCF, DragalinV, et al. Adaptive designs in clinical drug development: Opportunities, challenges, and scope reflections following PhRMA’s November 2006 workshop. J Biopharm Stat 2007; 17: 957–64.
3. ChowSC and ChangM. Adaptive design methods in clinical trials – A review. Orphanet J Rare Dis 2008; 3: 11.
4. CoffeyCS and KairallaJA. Adaptive clinical trials: Progress and challenges. Drugs RD 2008; 9: 229–42.
5. BretzF, BransonM, BurmannCF, et al. Adaptivity in drug discovery and development. Drug Dev Res 2009; 70: 169–90.
6. BretzF, KoenigF, BrannathW, et al. Adaptive designs for confirmatory clinical trials. Stat Med 2009; 28: 1181–1217.
7. EMEA. Reflection paper on methodological issues in confirmatory clinical trials with flexible design and analysis plan. EMEA (European Medicines Agency) 2007.
8. Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics Draft Guidance. (Accessed May 2010.)
9. HungHMJ, O’NeillRT, WangSJ, et al. A regulatory view on adaptive/flexible clinical trial design. Biometrical J 2006; 3: 1–9.
10. GaydosB, KramsM, PerevozskayaI, et al. Adaptive dose-response studies. Drug Inf J 2006; 40: 451–61.
11. Garrett-MoyerE. The continual reassessment method for dose-finding studies: A tutorial. Clin Trials 2006; 3: 57–71.
12. BretzF, HsuJ, PinheiroJ, et al. Dose finding – A challenge in statistics. Biometrical J 2008; 50: 480–504.
13. WestM and HarrisonPJ. Bayesian Forecasting and Dynamic Models. Springer-Verlag: New York, 1997.
14. BornkampB, BretzF, DmitrienkoA, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2007; 17: 965–95.
15. ProschanMA, LanKKG, WittesJT. Statistical Monitoring of Clinical Trials: A unified approach. Springer: New York, 2006.
16. RosenbergerWF. Randomized play-the-winner clinical trials: Review and recommendations. Control Clin Trials 1999; 20: 328–42.
17. HardwickJP and StoutQF. Bandit strategies for ethical sequential allocation. Control Clin Trials 1991; 23: 421–24.
18. TavesDR. The use of minimization in clinical trials. Contemp Clin Trials 2010; 31: 180–84.
19. BauerP and KohneK. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029–41.
20. ProschanMA and HunsbergerSA. Designed extension of studies based on conditional power. Biometrics 1995; 51: 1315–24.
21. LehmacherW and WassmerG. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286–90.
22. CuiL, HungHMJ and WangS. Modifications of sample size in group sequential clinical trials. Biometrics 1999; 55: 853–57.
23. MullerHH and SchaferH. Adaptive group sequential designs for clinical trials: Combining the advantages of adaptive and classical group sequential approaches. Biometrics 2001; 57: 886–91.
24. MehtaCR and PatelNR. Adaptive, group sequential, and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250–69.
25. TsiatisAA and MehtaC. On the inefficiency of the adaptive design for monitoring clinical trials. Biometrika 2003; 90: 367–78.
26. JennisonC and TurnbullBW. Efficient group sequential designs when there are several effect sizes under consideration. Stat Med 2006; 25: 917–32.
27. WittesJ and BrittainE. The role of internal pilot studies in increasing the efficiency of clinical trials. Stat Med 1990; 9: 65–72.
28. ProschanMA. Two-stage sample size re-estimation based on a nuisance parameter: A review. J Biopharm Stat 2005; 15: 559–74.
29. FriedeT and KieserM. Sample size recalculation in internal pilot study designs: A review. Biometrical J 2006; 48: 537–55.
30. ProschanMA. Sample size re-estimation in clinical trials. Biometrical J 2009; 51: 348–57.
31. KaufmanP, ThompsonJLP, LevyG, et al. Phase II trial of CoQ10 for ALS find insufficient evidence to justify phase III. Ann Neurol 2009; 66: 235–44.
32. RavinaB and PaleschY. The phase II futility clinical trial design. Prog Neurother Neuropsychopharmacol 2007; 2: 27–38.
33. KramsM, LeesKR, HackeW, et al. Acute stroke therapy by inhibition of neutrophils (ASTIN): An adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–48.
34. HoTW, MannixLK, FanX, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304–12.
35. WhelanHT, CookJD, Amlie-LefondCM, et al. Practical model-based dose finding in early-phase clinical trials: Optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children. Stroke 2008; 39: 2627–36.
36. ElkindMSV, SaccoRL, MacArthurRB, et al. High-dose lovastatin for acute ischemic stroke: Results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART). Cerebrovasc Dis 2009; 28: 266–275.
37. HaleyEC, ThompsonJLP, GrottaJC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: Results of a prematurely terminated randomized clinical trial. Stroke 2010; 41: 707–711.
38. OlesenJ, DienerH, HusstedtIW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. New Engl J Med 2004; 350: 1104–10.
39. QuinlanJA and KramsM. Implementing adaptive designs: Logistical and operational considerations. Drug Information Journal 2006; 40: 437–444.
40. QuinlanJ, GaydosB, MacaJ, et al. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development. Clin Trials 2010; 7: 167–73.
41. BurtonA, AltmanDG, RoystonP, et al. The design of simulation studies in medical statistics. Stat Med 2006; 25: 4279–92.
42. GaydosB, AndersonKM, BerryD, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J 2009; 43: 539–56.